00:25:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 X-dag ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma
2023-05-05 X-dag ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 X-dag ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma
2019-02-04 X-dag ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2024-08-28 10:01:00

Finnish ice hockey league (Liiga) team KalPa has extended its agreement for the PolarCap® System until 2027. KalPa has used PolarCap® over the past two seasons for the treatment of players suffering from concussions, with positive experience.

PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussions. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

Finnish top club KalPa are one of several clubs that have chosen to extend their current contracts with PolarCool. It was also recently announced that the Swedish champions Skellefteå AIK extended their agreement until 2027. In 2022 KalPa was the first club in Finland to implement treatment with PolarCap® in its concussion routines.

The club's positive experiences, alongside the compelling results from the published 5-year PolarCap® study, clearly demonstrate the value of continued PolarCap® use and form the basis for KalPa's decision to extend the agreement.

KalPa's CEO Toni Saksman comments:

-I am very pleased with the opportunity we have to be able to treat our players with PolarCap® in the acute phase if they suffer a concussion. For KalPa, the safety and well-being of our players is a priority and actively showing that we take care of our players in the best possible way is something we value. A healthy player is crucial for us as a club and team, but above all for the players themselves.

PolarCool CEO Erik Andersson comments:

-KalPa is another example of customer satisfaction for the PolarCap® System. We now see an increasing number of customers entering a second or third contract period. It is a receipt for the value we create for our customers. Our ambition is for the establishment to gain further momentum in Liiga as we notice that many clubs are awaiting a response from the clubs that were the first to implement PolarCap®.

The agreement with KalPa is strategically important, even if the financial significance of individual agreements is limited.